Stock Market & Financial Investment News

News Breaks March 11, 2013 06:49 EDT BDSI BioDelivery Sciences upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded BioDelivery Sciences citing the competitive position of the company's chronic pain treatment BBCP. The firm raised its price target for shares to $8 from $5. News For BDSI From The Last 14 Days Check below for free stories on BDSI the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 9, 2013 16:55 EDT BDSI BioDelivery Sciences' Clondine Topical Gel has $300M+ commercial potential Subscribe for More Information 16:52 EDT BDSI BDSI's Phase 3 trials for BEMA Buprenorphine to finish late 2013 or early 2014 Subscribe for More Information 16:48 EDT BDSI BioDelivery Sciences' NDA for Bunavail on track for mid-summer 2013 Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.